View Agent
| Agent Info | |
| Agent: | crizotinib |
| Synonyms: | Xalkori (TN) |
| Drug Status For Certain Diseases: | ALK-positive advanced or metastatic non-small-cell lung cancer(approved) |
| Classification: | 1st-generation, potent, orally available, ATP-competitive, small-molecule inhibitor of ALK and c-Met receptor tyrosine kinase, with half maximum inhibitory concentration values of 5–25 nmol/L |
| Target: | Hepatocyte growth factor receptor ALK ROS1 |
| KEGG Pathway: | PI3K-Akt signaling pathway Central carbon metabolism in cancer Focal adhesion Rap1 signaling pathway Ras signaling pathway Pathways in cancer Melanoma Cytokine-cytokine receptor interaction Bacterial invasion of epithelial cells Epithelial cell signaling in Helicobacter pylori infection Renal cell carcinoma Transcriptional misregulation in cancer Adherens junction Axon guidance Endocytosis Proteoglycans in cancer MicroRNAs in cancer |
| Wiki Pathway: | miR-targeted genes in epithelium - TarBase Extracellular vesicle-mediated signaling in recipient cells TGF beta Signaling Pathway Signaling of Hepatocyte Growth Factor Receptor Semaphorin interactions miR-targeted genes in lymphocytes - TarBase Signaling Pathways in Glioblastoma Focal Adhesion miR-targeted genes in squamous cell - TarBase miR-targeted genes in muscle cell - TarBase Spinal Cord Injury |